春节过后,国产创新药出海热潮丝毫不减,持续书写着中国医药创新的全球化新篇章。进入3月份,创新药出海又传来捷报,中国生物制药宣布达成15.3 亿美金创新药授权交易。3月4日,中国生物制药公告,公司附属公司正大天晴与赛诺菲全资附属公司就JAK/ROCK抑制剂罗伐昔替尼(商品名:安煦 )在全球范围内的开发、生产及商业化订立独家授权协议。资料显示,罗伐昔替尼是一款新型、强效口服小分子JAK/ROCK抑制剂...
Source Link春节过后,国产创新药出海热潮丝毫不减,持续书写着中国医药创新的全球化新篇章。进入3月份,创新药出海又传来捷报,中国生物制药宣布达成15.3 亿美金创新药授权交易。3月4日,中国生物制药公告,公司附属公司正大天晴与赛诺菲全资附属公司就JAK/ROCK抑制剂罗伐昔替尼(商品名:安煦 )在全球范围内的开发、生产及商业化订立独家授权协议。资料显示,罗伐昔替尼是一款新型、强效口服小分子JAK/ROCK抑制剂...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.